Nasdaq

Quest Diagnostics to Introduce Ki-67 IHC MIB-1 pharmDx, the First Companion Diagnostic for Eli Lilly and Company's Verzenio® (abemaciclib), a CDK4/6 Inhibitor for Certain ...

As the First Laboratory to Validate Ki-67 IHC MIB-1 pharmDx (Dako Omnis), Quest Plans to Make Testing Available Nationally by the End of October SECAUCUS, N.J., Oct. 18, 2021 /PRNewswire/ -- Quest ...
Business Wire

Agilent Receives FDA Companion Diagnostic Approval for Ki-67 IHC MIB-1 pharmDx in High-Risk Early Breast Cancer

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced its Ki-67 IHC MIB-1 pharmDx (Dako Omnis) is now FDA approved as an aid in identifying patients with early ...
Nasdaq

Quest To Introduce Companion Diagnostic Ki-67 IHC MIB-1 PharmDx In High-Risk Early Breast Cancer

(RTTNews) - Quest Diagnostics (DGX), on Monday, said it has decided to introduce clinical laboratory testing using Ki-67 IHC MIB-1 pharmDx (Dako Omnis) immunohistochemistry companion diagnostic. The ...